Page last updated: 2024-08-21

cyclopentane and sorafenib

cyclopentane has been researched along with sorafenib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bie, P; Fang, L; Jiang, P; Li, G; Lin, X; Wu, D; Xie, CM; Yang, Z; Yin, L; Zhang, J; Zhang, L; Zhong, C	1

Other Studies

1 other study(ies) available for cyclopentane and sorafenib

Article	Year
Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib. Oncology reports, 2019, Volume: 41, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclopentanes; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; NEDD8 Protein; Neoplasm Proteins; NF-KappaB Inhibitor alpha; Pyrimidines; Sorafenib; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays	2019

Article

Year

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.

Oncology reports, 2019, Volume: 41, Issue:6

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclopentanes; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; NEDD8 Protein; Neoplasm Proteins; NF-KappaB Inhibitor alpha; Pyrimidines; Sorafenib; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays

2019